Literature DB >> 11054521

Dermatofibrosarcoma protuberans: treatment results of 35 cases.

L M Sun1, C J Wang, C C Huang, S W Leung, H C Chen, F M Fang, E Y Huang, S P Lee.   

Abstract

BACKGROUND AND
PURPOSE: This study evaluates the treatment results of patients with dermatofibrosarcoma protuberans. PATIENTS AND METHODS: Between August 1987 and July 1998, 35 consecutive patients with pathologically proved dermatofibrosarcoma protuberans received surgery with or without radiation therapy. Their treatment results were analyzed retrospectively.
RESULTS: The patient ages ranged from 5 to 67 years (median 37 years). There were 24 males and 11 females. The anatomic sites of tumor were: trunk in 21, extremity in eight, and head and neck region in six. The maximal dimension of tumor ranged from 1.5 to 25 cm. Surgery techniques included local excision and wide excision with or without graft or flap. Adjuvant radiation therapy was given to 11 patients, with a dose ranging from 46 to 68 Gy (one pre-operative, ten post-operative). At a median follow-up of 50 months (range 11-131 months), there were 11 patients (nine patients without radiation therapy) who developed local failure. Salvage therapy (excision with or without radiation therapy) was given to all of them, and ten achieved disease control. Some patients had treatment-related moderate cosmetic or functional problems.
CONCLUSIONS: Dermatofibrosarcoma protuberans is a malignancy of a high cure rate, and adjuvant radiation therapy can reliably decrease the local recurrence rate and prevent mutilation and functional deficit caused by repeated surgery.

Entities:  

Mesh:

Year:  2000        PMID: 11054521     DOI: 10.1016/s0167-8140(00)00228-0

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  21 in total

Review 1.  Targeted therapy for dermatofibrosarcoma protuberans.

Authors:  Thomas A Abrams; Scott M Schuetze
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

Review 2.  Dermatofibrosarcoma protuberans with fibrosarcomatous transformation of the head and neck.

Authors:  Nikolaos Angouridakis; Panagiotis Kafas; Waseem Jerjes; Stefanos Triaridis; Tahwinder Upile; Georgios Karkavelas; Angelos Nikolaou
Journal:  Head Neck Oncol       Date:  2011-02-04

3.  Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy.

Authors:  Ryan C Fields; Meera Hameed; Li-Xuan Qin; Nicole Moraco; Xiaoyu Jia; Robert G Maki; Samuel Singer; Murray F Brennan
Journal:  Ann Surg Oncol       Date:  2010-09-16       Impact factor: 5.344

4.  Excellent survival of pediatric dermatofibrosarcoma protuberans in Taiwanese.

Authors:  Chun-Ru Chien; Yih-Leong Chang; Dong-Tsamnn Lin; Rong-Sen Yang
Journal:  Pediatr Surg Int       Date:  2006-11-16       Impact factor: 1.827

Review 5.  Dermatofibrosarcoma Protuberans.

Authors:  Alvaro E Acosta; Catalina Santa Vélez
Journal:  Curr Treat Options Oncol       Date:  2017-08-10

Review 6.  Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.

Authors:  Takeshi Iwasaki; Hidetaka Yamamoto; Yoshinao Oda
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

7.  Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib.

Authors:  Yan Fu; Huanrong Kang; Hui Zhao; Jia Hu; Huanhuan Zhang; Xiaosong Li; Nan Du; Yitao Huang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 8.  Current treatment options in dermatofibrosarcoma protuberans.

Authors:  Doreen Lemm; L-O Mügge; T Mentzel; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-10       Impact factor: 4.553

Review 9.  [Dermatofibrosarcoma protuberans].

Authors:  S Ugurel
Journal:  Hautarzt       Date:  2008-11       Impact factor: 0.751

10.  Dermatofibrosarcoma protuberans with contiguous infiltration of the underlying bone.

Authors:  Mandeep Kumar Garg; Mukesh Kumar Yadav; Suruchi Gupta; Narender Kumar; Niranjan Khandelwal
Journal:  Cancer Imaging       Date:  2009-09-29       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.